Patent US2347013A successfully refreshed from Google Patents.
Patent EP0300988A2 successfully refreshed from Google Patents.
EP0300988A2
Expired / Lapsed
EP
⏱️ 0.0 years remaining
Tissue factor inhibitor
Assignee: University of Washington
•
Filing: 1988-07-22
•
Granted: —
•
Expires: 2008-07-22
Abstract
Abstract A purified tissue factor inhibitor is provided which has the following characteristics: A. it exists in two forms, TFl 1 migrating at about 37-40,000 daltons and TFl 2 at about 25-26,000 daltons, as determined by sodium dodecylsulfate polyacrylamide gel electrophoresis, B. it has a partial N-terminal amino acid sequence as follows: wherein X-X has not been determined, and C. it exhibits inhibitory activity to Factor X a .
Inventors
- 👤 George John Broze, Jr.
Bibliographic Details
Application Number
—
Jurisdiction
EP
Data Source
google_patents
Last Synchronized
2026-11-08 01:10
CPC Classifications
C; C07; C07K; C07K16/00; C07K16/38; A; A61; A61P; A61P7/00; A61P7/02; C07K14/00; C07K14/81; C07K14/8107; C07K14/811; C07K14/8114; A61K; A61K39/00; A61K2039/505; A61K38/00
Claims Analysis
Total Claims: 9
Claim 1
Independent Claim
63 words
Tissue factor inhibitor having the following characteristics: A. it exists in two forms, TFI 1 migrating at about 37-40,000 daltons and TF1 2 at about 25-26,000 daltons, as determined by sodium dodecylsulfate polyacrylamide gel electrophoresis, B. it has a partial N-terminal amino acid sequence as follows: wherein X-X has not been determined, and C. it exhibits inhibitory activity to Factor X a .
Claim 2
Dependent Claim
63 words
Tissue factor inhibitor having the following characteristics: A. it exists in two forms, TFI 1 migrating at about 37-40,000 daltons and TF1 2 at about 25-26,000 daltons, as determined by sodium dodecylsulfate polyacrylamide gel electrophoresis, B. it has a partial N-terminal amino acid sequence as follows: wherein X-X has not been determined, and C. it exhibits inhibitory activity to Factor X a .
Claim 3
Dependent Claim
19 words
Tissue factor inhibitor of Claim 1 isolated from the conditioned medium of HepG2 cells grown in nutrient culture medium.
Claim 4
Independent Claim
47 words
The method of isolating tissue factor inhibitor from the conditioned medium of HepG2 cells comprising: A. CdC1 2 precipitation, B. Factor X a Affi-Gel 15 affinity chromatography of the resolubilized precipitate, and C. Superose 12 gel filtration of the fractions from the affinity chromatography containing TFI activity.
Claim 5
Independent Claim
47 words
The method of isolating tissue factor inhibitor from the conditioned medium of HepG2 cells comprising: A. CdC1 2 precipitation, B. Factor X a Affi-Gel 15 affinity chromatography of the resolubilized precipitate, and C. Superose 12 gel filtration of the fractions from the affinity chromatography containing TFI activity.
Claim 6
Independent Claim
65 words
The method of isolating tissue factor inhibitor from the conditioned medium of HepG2 cells comprising: A. CdC1 2 precipitation, B. diisopropylphosphoryl (ipr 2 P) -Factor Xa Affi-Gel 15 affinity chromatography of the resolubilized precipitate, C. Sephadex G-75 gel filtration of the fractions from the affinity chromatography containing TFI activity, and D. Mono Q ion-exchange chromatography of the fractions from the gel filtration containing TFI activity.
Claim 7
Independent Claim
65 words
The method of isolating tissue factor inhibitor from the conditioned medium of HepG2 cells comprising: A. CdC1 2 precipitation, B. diisopropylphosphoryl (ipr 2 P) -Factor Xa Affi-Gel 15 affinity chromatography of the resolubilized precipitate, C. Sephadex G-75 gel filtration of the fractions from the affinity chromatography containing TFI activity, and D. Mono Q ion-exchange chromatography of the fractions from the gel filtration containing TFI activity.
Claim 8
Dependent Claim
27 words
The method of inhibiting Factor Xa production in a mammal comprising administering to said mammal an effective amount of tissue factor inhibitor as defined in Claim 1.
Claim 9
Dependent Claim
31 words
The method of inhibiting Factor Vll a /TF enzymatic complex formation in a mammal comprising administering to said mammal an effective amount of tissue factor inhibitor as defined in Claim 1.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
Maintenance schedule is calculated for granted US utility patents.